Adverse Events with Biomedicines Prevention Through Understanding /
This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicines” – monoclonal antibodies, fusion proteins, and cytokines – that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are cover...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Language: | English |
| Published: |
Milano :
Springer Milan : Imprint: Springer,
2014.
|
| Edition: | 1st ed. 2014. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-88-470-5313-7 |
Table of Contents:
- Part I General Aspects: 1 Introduction
- 2 Adverse drug events to biomedicines
- 3 Systemic syndromes caused by biomedicines
- Part II Monoclonal antibodies: 4 Monoclonal antibodies
- 5 Abciximab
- 6 Adalimumab
- 7 Alemtuzumab
- 8 Basiliximab
- 9 Belimumab
- 10 Bevacizumab
- 11 Brentuximab
- 12 Canakinumab
- 13 Catumaxomab
- 14. Certolizumab
- 15 Cetuximab
- 16 Daclizumab
- 17 Denosumab
- 18 Eculizumab
- 19 Edrecolomab
- 20 Efalizumab
- 21 Gemtuzumab
- 22 Golimumab
- 23 Ibritumomab
- 24 Infliximab
- 25 Ipilimumab
- 26 Muromonab
- 27 Natalizumab
- 28 Nimotuzumab
- 29 Ofatumumab
- 30 Omalizumab
- 31 Palivizumab
- 32 Panitumumab
- 33 Pertuzumab
- 34 Ranibizumab
- 35 Rituximab
- 36 Tocilizumab
- 37 Tositumomab
- 38 Trastuzumab
- 39 Ustekinumab
- Part III Fusion proteins: 40 Fusion proteins
- 41 Abatacept
- 42 Aflibercept
- 43 Alefacept
- 44 Belatacept
- 45 Etanercept
- 46 Rilonacept
- 47 Romiplostim
- Part IV Cytokines : 48 Cytokines
- 49 Interleukins
- 50 Denileukin-diftitox
- 51 Anakinra
- 52 Interferons
- 53 Hemopoietic stimulatory factors
- 54 Myelopoietic stimulatory factors
- 55 Thrombopoietic stimulatory factor
- 56 Pluripotent growth factors
- 57 Epidermal growth factors
- Part V Overview: 58 Biomedicines as adverse event inducers
- 59 Conclusions and perspectives.